AstraZeneca Pharma India

₹6,480As of Sun 8 Nov 2026, 12:00 UTC
NSE:ASTRAZENHealthcare
Country India
PE (Fwd) 63.87
TSR 10Y CAGR 20.67%
Div yield 0.56%
ROE —
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.22
PE TTM 86.38
TSR TTM (31.88%)
Mkt cap ₹161.8B
ROIC —
SE Grade™
Value
Quality
Moat
1Y Price
Reference
₹7,126
9.97%
(86.61%)
Price above Reference Value
FY23
FY24
FY25
FY26
Earnings per share₹
39.72
64.60
46.30
75.01
61.19%
62.66%
(28.34%)
62.02%
Revenue₹B
10.03
12.96
17.16
22.76
24.50%
29.17%
32.48%
32.59%
TTM
FYE 31 Mar INR
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
FY2027E
Trend
5Y
10Y
Peers
22.76
Revenue₹B
—
—
—
—
—
8.056
10.03
12.96
17.16
22.76
26.57
29.64%
29.64%
27
32.59
Revenue growth%
—
—
—
—
—
—
24.50
29.17
32.48
32.59
16.76
30.82
—
87
39.15
Gross margin%
—
—
—
—
—
60.66
63.51
53.63
43.55
39.15
39.24
53.63
53.63
24
10.27
Operating margin%
—
—
—
—
—
8.61
14.84
13.23
12.52
10.27
10.47
12.52
12.52
27
8.24
Net margin%
—
—
—
—
—
7.65
9.90
12.47
6.74
8.24
8.31
8.24
8.24
38
86.38
P/E ratio (avg)x
—
—
—
—
—
146.1
78.74
78.46
160.5
117.8
73.36
117.8
117.8
12
69.30
EV/EBITx
—
—
—
—
—
129.8
52.52
73.92
86.47
94.55
58.25
86.47
86.47
0
—
FCF yield (avg)%
—
—
—
—
—
—
—
—
—
—
—
—
—
41
—
FCF margin%
—
—
—
—
—
—
—
—
—
—
—
—
—
52
—
FCF / Net incomex
—
—
—
—
—
—
—
—
—
—
—
—
—
92
—
ROIC%
—
—
—
—
—
—
—
—
—
—
—
—
—
86
—
Return on equity%
—
—
—
—
—
—
—
—
—
—
—
—
—
88
—
Return on assets%
—
—
—
—
—
—
—
—
—
—
—
—
—
74
75.01
EPS₹
—
—
—
—
—
24.64
39.72
64.60
46.30
75.01
88.33
32.09%
32.09%
—
62.02
EPS growth%
—
—
—
—
—
—
61.19
62.66
(28.34)
62.02
17.76
61.60
—
50
—
Bookvalue per sh₹
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
FCF per share₹
—
—
—
—
—
—
—
—
—
—
—
—
—
—
36.00
Dividend per sh₹
—
—
—
—
—
10.00
16.00
24.00
32.00
36.00
38.50
37.74%
37.74%
—
0.56
Div yield (avg)%
—
—
—
—
—
0.28
0.51
0.47
0.43
0.41
0.59
0.43
0.43
23
47.99
Payout ratio%
—
—
—
—
—
40.58
40.29
37.15
69.12
47.99
43.59
40.58
40.58
50
25.00
Shares (diluted)M
—
—
—
—
—
25.00
25.00
25.00
25.00
25.00
◌25.00
—
—
52
—
Buyback yield%
—
—
—
—
—
—
—
—
—
—
◌—
—
—
52
—
D/E ratiox
—
—
—
—
—
—
—
—
—
—
—
—
—
55
162.0
Enterprise value₹B
—
—
—
—
—
90.01
78.18
126.7
185.8
221.0
162.0
25.18%
25.18%
53
—
LT debt₹M
—
—
—
—
—
—
—
—
—
—
—
—
—
17
Peers (US$1.713B)
Cap (US$)
PE
1.827B
24.12x
1.686B
12.63x
1.708B
19.00x
Capital
TTM
5Y
10Y
Leveragex
—
—
—
EBIT/Intx
52.06
142.9
142.9
Own earn%
—
—
—
Sh yield%
0.56
0.45
0.45
Owners
Insiders/Inst%
6.18
9.14
Short interest%
—
SBC / revenue%
0.02
Record
10Y
Profitable years
5/5
Revenue growth years
4/4
EPS growth years
3/4
Dividend streakyrs
4
Op margin range%
9–15
$1 testx
—
Incr. ROIC%
—

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cancers, including pancreatic cancer, certain blood cancers, and cancers within breast, lung, ovary, and prostate; rare diseases; and cardiovascular, renal and metabolism, and respiratory and immunology, as well as diabetes.

Growth vs revenue
Latest
Trend
4Y CAGR
Rel growth
Revenue
₹22.76B
29.64%
1.00×
Cost of revenue
₹13.85B
44.58%
1.55×
Operating expenses
₹6.572B
11.89%
0.55×
Revenue by region
No breakdown available
Reinvestment returns
n/m
Trend
Reinvestment rate
n/m
-
Return on capital
n/m
-
Spread over hurdle
n/m
-